• Test Code:
  • Department:
  • Test Synonyms:
    Neuromuscular disordersNemaline myopathyCentral core disease Myotubular myopathyACTA1BIN1CFL2CNTN1DNM2 KBTBD13MTM1MYF6MYH7NEBRYR1SEPN1TNNT1TPM2TPM3
  • CPT Code(s):
    Contact KDL for billing information
Background:

Neuromuscular disorders are a group of heterogeneous conditions affecting the nervous system that controls muscle movements. Congenital myopathies are a group of genetic conditions and can be autosomal dominant, recessive or X-linked. Typical clinical manifestations include hypotonia, muscle weakness, and delayed motor developmental milestones. Cardiac conditions and joint dislocations can also be observed. This test includes genes associated with central core disease, nemaline myopathy, and myotubular myopathy.

Reasons for Referral:

  • Abnormal serum creatine kinase levels
  • Delayed movement milestones
  • Muscle weakness with signs of structural abnormalities of myofibers observed in biopsy
  • Abnormal electromyography (EMG)
  • Abnormal nerve conduction studies (NCS)
  • Positive family history (targeted testing is available if familial mutation is known)
  • Carrier testing

For detailed information and ordering instructions, please refer to Full Gene Analysis (1240). Genes may be added or removed from the list below if clinically indicated. Exon-centric deletion/duplication analysis (1340) is also available if indicated. 

Congenital Muscular Myopathy Panel (15 genes):
ACTA1, BIN1, CFL2, CNTN1, DNM2, KBTBD13, MTM1, MYF6, MYH7, NEB, RYR1, SEPN1, TNNT1, TPM2, TPM3 

Methodology:

Specimen Requirements:

Test Performed (Days):

Turn Around Time:

Shipment Sensitivity Requirements:

References:

  1. Curr Opin Neurol. 2001 Oct;14(5):575-82. GeneReviews

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More